Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GUSTO II trial

P Aylward1

  • 1Flinders Medical Centre, Adelaide, SA.

Australian and New Zealand Journal of Medicine
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

The GUSTO II trial compares heparin with recombinant hirudin for acute coronary syndromes. This study evaluates antithrombin therapy effectiveness in unstable angina and myocardial infarction patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical features of patients who are admitted under different criteria of the Irish Mental Health Act 2001: a retrospective cohort study.

Irish journal of psychological medicine·2025
Same author

A four-year longitudinal evaluation of the impact of the COVID-19 pandemic on patients with a range of mental health disorders.

Irish journal of psychological medicine·2024
Same author

Morbidity, mortality and economic burden of renal impairment in cardiac intensive care.

Internal medicine journal·2006
Same author

Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.

Circulation·2000
Same author

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.

Lancet (London, England)·1999
Same author

Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators.

The New England journal of medicine·1999

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Acute coronary syndromes (ACS) require effective antithrombin therapy.
  • Heparin is a standard treatment, but newer agents like recombinant hirudin offer potential advantages.

Purpose of the Study:

  • To investigate the efficacy and safety of recombinant hirudin compared to heparin in ACS patients.
  • To evaluate antithrombin therapy in both primary treatment and post-thrombolysis settings for ACS.

Main Methods:

  • A global, multifactorial clinical trial involving 12,000 patients.
  • Comparison of standard heparin doses versus recombinant hirudin.
  • Inclusion of patients with unstable angina and myocardial infarction (MI) unsuitable for thrombolysis, as well as post-thrombolysis patients.

Related Experiment Videos

Main Results:

  • The GUSTO II trial is designed to provide significant data on antithrombin therapy outcomes.
  • Results will elucidate the comparative effectiveness of heparin and recombinant hirudin in ACS management.

Conclusions:

  • The findings will inform clinical practice guidelines for antithrombin use in ACS.
  • This trial aims to establish the role of recombinant hirudin in managing acute coronary syndromes.